据悉,CBD Life Sciences计划以1400万美元收购纽约两家大麻药房,以在2027年之前在纽约大麻市场上增强市场存在. CBD Life Sciences plans to acquire two New York cannabis dispensaries for $14M to boost market presence in the $4.2B NY cannabis market by 2027.
作为领先的CBD公司,CBD生命科学公司计划在纽约两家大麻药房中获得战略利益, 合计价值1400万美元. CBD Life Sciences, Inc., a leading CBD company, plans to acquire strategic interests in two New York cannabis dispensaries with a combined value of $14M. 收购的目的是到2027年提高公司在迅速增长的4.2B纽约大麻市场上的市场存在和利润率。 The acquisitions aim to boost the company's market presence and profitability in the rapidly growing $4.2B New York cannabis market by 2027. 这些举措与CBD生命科学在关键市场扩张,增加收入来源和提高利能力的增长战略一致. These moves align with CBD Life Sciences' growth strategy of expanding in key markets, increasing revenue streams, and enhancing profitability.